|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.120 USD | +3.38% |
|
+1.32% | -8.49% |
| 05-12 | Harvard Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 05-12 | Harvard Bioscience, Inc., Q1 2026 Earnings Call, May 12, 2026 |
Company Valuation: Harvard Bioscience, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 27.6 | - |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | -7.42% | - |
| Enterprise Value (EV) | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 27.6 | 27.6 |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | -7.42% | 0% |
| P/E | -705x | -12x | -66.9x | -7.54x | -0.52x | -3.12x | -13.9x |
| PBR | 3.65x | 1.64x | 3.18x | 1.47x | 2.16x | 3.62x | 5.23x |
| PEG | - | -0x | 1x | -0x | -0x | 0x | 0.2x |
| Capitalization / Revenue | 2.42x | 1.02x | 2.03x | 0.98x | 0.34x | 0.31x | 0.29x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.31x | 0.29x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 3.21x | 2.94x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 4.45x | 3.21x |
| EV / FCF | 0x | -0x | 0x | -0x | 0x | -9.52x | -138x |
| FCF Yield | 0.02% | -0.38% | 5.36% | -1.31% | 18.3% | -10.5% | -0.72% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.1 | -2.3 | -0.8 | -2.8 | -12.8 | -1.96 | -0.44 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 118.9 | 113.3 | 112.2 | 94.14 | 86.55 | 88.6 | 94.2 |
| EBITDA 1 | 18.5 | 10.84 | 14.55 | 7.196 | 8.081 | 8.6 | 9.4 |
| EBIT 1 | 16.72 | 9.497 | 13.11 | 5.294 | 6.163 | 6.2 | 8.6 |
| Net income 1 | -0.288 | -9.516 | -3.415 | -12.4 | -56.7 | -9.05 | -2.05 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 70.500 | 27.700 | 53.500 | 21.100 | 6.688 | 6.120 | 6.120 |
| Nbr of stocks (in thousands) | 4,081 | 4,166 | 4,269 | 4,362 | 4,458 | 4,510 | - |
| Announcement Date | 3/8/22 | 3/9/23 | 3/7/24 | 3/12/25 | 3/12/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.02x | - | - | - | 26.97M | |
| 28.74x | 5.14x | 19.72x | 0.32% | 214B | |
| 33.22x | 6.08x | 19.24x | 0.74% | 140B | |
| 39.64x | 10.29x | 22.77x | -.--% | 128B | |
| 16.48x | 3.47x | 11.19x | -.--% | 68.46B | |
| 32.54x | 6.61x | 20.93x | -.--% | 48.18B | |
| 19.04x | 2.18x | 11.3x | 2.76% | 45.56B | |
| 27.33x | 5.44x | 18.58x | 0.73% | 39.69B | |
| 46.53x | 6.48x | 19.91x | -.--% | 37.69B | |
| 19.73x | 5.19x | 13.32x | 1.16% | 30.14B | |
| Average | 26.02x | 5.65x | 17.44x | 0.63% | 75.17B | |
| Weighted average by Cap. | 30.42x | 6.04x | 18.63x | 0.48% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HBIO Stock
- Valuation Harvard Bioscience, Inc.
Select your edition
All financial news and data tailored to specific country editions
